Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma
Sponsor: Cortice Biosciences, Inc.
Terminated
Lack of Enrollment
Other terminated trials from Cortice Biosciences, Inc.
- Brain Lesions · Phase PHASE1 · Mar 2018
- Melanoma · Phase PHASE1 · Jul 2016
- Brain Neoplasms · Phase PHASE1/PHASE2 · Mar 2016
- Glioblastoma Multiforme · Phase PHASE2 · Dec 2015
- Medulloblastoma · Phase PHASE1/PHASE2 · Dec 2014
More terminations from Cortice Biosciences, Inc.
A PHASE1/PHASE2 clinical study on Neuroblastoma, this trial is terminated or withdrawn. The trial is conducted by Cortice Biosciences, Inc. and has accumulated 10 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Oct 2023 — May 2024 [monthly]
Terminated PHASE1_PHASE2
▶ Show 5 earlier versions
-
May 2022 — Oct 2023 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — May 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cortice Biosciences, Inc.
- Giselle Sholler
For direct contact, visit the study record on ClinicalTrials.gov .